Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review-Reference-Cited by-同舟云学术

Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review

Published:2021-02-22 Issue:3 Volume:21 Page:381-393
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Yu Anthony¹,Huang Eva¹,Abe Momoka¹,An Kang¹,Park Sun-Kyeong²,Park Chanhyun¹^ORCID

Affiliation:

1. School of Pharmacy, Bouvé College of Health Sciences, Northeastern University, Boston, MA, United States

2. College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2021.1886928

Reference46 articles.

1. American Cancer Society: cancer Facts and Figures 2020.https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed 2021 Jan 3.

2. Lung Cancer - Non-Small Cell - Statistics. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Published May 28, 2020. Accessed 2020 Dec 12.

3. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

4. The 2015 World Health Organization Classification of Lung Tumors

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety and efficacy of binimetinib for lung cancer: a systematic review;BMC Pulmonary Medicine;2024-08-01

2. Cost-effectiveness of immunotherapies for advanced squamous non-small cell lung cancer: a systematic review;BMC Cancer;2024-03-06

3. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC);PharmacoEconomics;2023-06-03

4. Co-existing squamous cell carcinoma and chronic myelomonocytic leukemia with ASXL1 and EZH2 gene mutations: A case report;World Journal of Clinical Cases;2023-05-26

5. Sponsorship bias in oncology cost effectiveness analysis;Journal of Clinical Epidemiology;2023-04